Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
A phase 3 trial of Carboplatin, Docetaxel, Goserelin / leuprolide, Pertuzumab, HLX11, Trastuzumab and Trastuzumab biosimilars in Breast cancer, run by National Cancer Institute (NCI), completed.
Overview
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer is a phase 3 interventional study registered as NCT02003209 by National Cancer Institute (NCI), with 315 participants recorded, started 2014-02-18 and reaching its primary completion in 2016-10-31. Interventions recorded: Aromatase Inhibition Therapy, Carboplatin, Cytology Specimen Collection Procedure, Docetaxel, Goserelin Acetate, Laboratory Biomarker Analysis, Pertuzumab, Quality-of-Life Assessment, Therapeutic Conventional Surgery, Trastuzumab, Whole Breast Irradiation. Conditions recorded: HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7.
Linked to the drug Trastuzumab biosimilars because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialChemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
Shares Trastuzumab biosimilars, Docetaxel, Breast cancer (all types), Trastuzumab and the tag pipeline.
- TrialMARGetuximab Or Trastuzumab (MARGOT)
Shares Trastuzumab biosimilars, Pertuzumab, Breast cancer (all types), Trastuzumab and the tag pipeline.
- TrialOptimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging
Shares Pertuzumab, Breast cancer (all types), Trastuzumab, Carboplatin and the tag pipeline.
- TrialRadiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
Shares Trastuzumab biosimilars, Trastuzumab and the tag pipeline.
- TrialAdjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea
Shares Goserelin / leuprolide (ovarian function suppression), Breast cancer (all types) and the tag pipeline.
- TrialA Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Shares Pertuzumab, Docetaxel, Trastuzumab and the tag pipeline.
- TrialA Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
Shares Pertuzumab, Docetaxel, Trastuzumab and the tag pipeline.
- TrialSix vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer
Shares Docetaxel, Breast cancer (all types), Trastuzumab and the tag pipeline.